CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

Immunotherapy utilizing chimeric antigen receptor T cell (CAR-T) therapy holds promise for hematologic malignancies, however, response rates and associated immune-related adverse effects widely vary among patients. Here we show, by comparing diversity and composition of the gut microbiome during dif...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yongxian, Li, Jingjing, Ni, Fang, Yang, Zhongli, Gui, Xiaohua, Bao, Zhiwei, Zhao, Houli, Wei, Guoqing, Wang, Yiyun, Zhang, Mingming, Hong, Ruimin, Wang, Linqin, Wu, Wenjun, Mohty, Mohamad, Nagler, Arnon, Chang, Alex H., van den Brink, Marcel R. M., Li, Ming D., Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461447/
https://www.ncbi.nlm.nih.gov/pubmed/36085303
http://dx.doi.org/10.1038/s41467-022-32960-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461447/
https://www.ncbi.nlm.nih.gov/pubmed/36085303
http://dx.doi.org/10.1038/s41467-022-32960-3

Ejemplares similares